Department of Cardiology, Carmel Medical Center, Heart Center, Haifa, Israel.
Department of Pediatrics, Clalit Health Care Organization, Carmel Medical Center, Haifa, Israel.
Future Cardiol. 2024;20(10):581-590. doi: 10.1080/14796678.2024.2406651. Epub 2024 Oct 9.
This systematic review evaluated the impact of a chronic total occlusion (CTO) in a non-infarct-related artery (non-IRA) on clinical outcomes in acute coronary syndrome (ACS) patients and assessed the benefits of staged revascularization. We performed a comprehensive systematic review to provide further insight into the impact of a CTO in a non-IRA on clinical outcomes after ACS. Moreover, we review the currently available evidence on the clinical significance of staged revascularization for a CTO in a non-IRA patients with ACS and propose whether prophylactic CTO percutaneous coronary intervention (PCI) could improve outcomes in patients who subsequently develop an ACS. Our search identified 999 studies, from which 30 were selected and ten were included in the analysis. The results showed a trend of higher all-cause mortality and major adverse cardiac event rates in the culprit-only-PCI group compared with the multivessel (MV)-PC I group in ST elevation myocardial infarction patients, with varying statistical significance across different outcomes. This review highlights the significant impact of non-IRA CTOs in ACS. Successful CTO revascularization may provide benefits, particularly in ST elevation myocardial infarction, but the optimal management approach remains uncertain. The presence of a non-IRA CTO, especially in cardiogenic shock, predicts worse outcomes. Further research is warranted to determine the effective strategies to improve survival.
本系统评价评估了非梗死相关动脉(non-IRA)中的慢性完全闭塞(CTO)对急性冠脉综合征(ACS)患者临床结局的影响,并评估了分期血运重建的获益。我们进行了全面的系统评价,以进一步深入了解非 IRA 中的 CTO 对 ACS 后临床结局的影响。此外,我们回顾了目前关于 ACS 合并非 IRA 中 CTO 分期血运重建的临床意义的证据,并提出是否预防性 CTO 经皮冠状动脉介入治疗(PCI)可以改善随后发生 ACS 的患者的结局。我们的检索共确定了 999 项研究,从中选择了 30 项研究,10 项研究纳入分析。结果显示,在 ST 段抬高型心肌梗死患者中,与多血管(MV)-PCI 组相比,仅罪犯血管 PCI 组的全因死亡率和主要不良心脏事件发生率呈上升趋势,但不同结局的统计学意义不同。本综述强调了非 IRA CTO 在 ACS 中的重要影响。成功的 CTO 血运重建可能会带来获益,特别是在 ST 段抬高型心肌梗死中,但最佳的管理方法仍不确定。非 IRA CTO 的存在,尤其是在心源性休克中,预示着更差的结局。需要进一步的研究来确定改善生存的有效策略。